PEG-MGF

Dosing from the Literature

Published for muscle: nothing in people; the community doses come from online protocols, not trials (Dominikowski et al., 2026). Not published: any human dose; no trial exists.

No peer-reviewed study reports a dose of PEG-MGF in people, and its half-life has not been reported (Dominikowski et al., 2026). None of the animal studies cited on this page used PEG-MGF itself. The rows below are what online protocols describe.

What It Is

PEG-MGF is a polyethylene-glycol-conjugated analog of mechano growth factor. Understanding what it is requires first understanding its parent molecule — MGF — which is the C-terminal E-domain peptide of the insulin-like growth factor 1 (IGF-1) Ec splice variant. In human skeletal muscle, the IGF1 gene is alternatively spliced into three isoforms: IGF-1Ea (the dominant liver/systemic isoform producing circulating IGF-1), IGF-1Eb, and IGF-1Ec. The IGF-1Ec transcript is upregulated in skeletal muscle in response to mechanical loading — this is why the Ec-derived peptide is called "mechano growth factor." Cleaving the precursor yields mature IGF-1 and an E peptide, though for IGF-1Ec only the uncleaved precursor, not a free Ec peptide, has been detected so far (Philippou et al., 2014). Studies use a synthetic 24-amino-acid peptide from the end of the E domain, also called MGF (Mills et al., Am J Transplant 2007); in rat muscle, the early rise in MGF suggested that it triggers satellite cell (muscle stem cell) activation (Hill & Goldspink, 2003).

Native MGF has two critical pharmacological limitations for exogenous administration: (1) very short plasma half-life (approximately 5–7 minutes due to rapid enzymatic degradation), and (2) strictly local action — in natural physiology MGF is produced and consumed within the loaded muscle tissue, never reaching systemic circulation at meaningful concentrations.

PEG-MGF is meant to address these limitations by conjugating polyethylene glycol (PEG) — typically a 20–40 kDa linear or branched PEG — to the MGF peptide. PEG is a hydrophilic polymer that creates a "stealth shell" around the conjugated peptide, reducing proteolytic access, slowing renal clearance, and sometimes reducing immunogenicity. PEGylation is a well-established pharmacological strategy used in FDA-approved products including PEG-interferon (Pegasys, PegIntron), PEG-G-CSF (Neulasta), and PEG-adenosine deaminase (Adagen). For MGF, PEGylation is promoted commercially as a way to add stability and prolong exposure, but PEG-MGF's half-life has not been reported (Dominikowski et al., 2026).

The trade-off is pharmacological: native MGF is thought to act as a sharp, high-concentration local pulse that mimics the physiological mechano-response pattern, while PEG-MGF is meant to give a longer-lasting systemic signal. Whether the altered kinetic pattern produces equivalent biology is a genuine scientific question that has not been resolved by head-to-head in-vivo studies. Whether sustained low-level satellite cell activation is biologically equivalent to natural pulsatile activation is unresolved. PEG-MGF is marketed as a research compound, and none of the studies in this page's reference list tested it; effects seen with unmodified MGF peptides cannot be assumed to apply to it (Dominikowski et al., 2026).

Mechanism of Action

None of the studies below tested PEG-MGF itself; the MGF findings come from unmodified MGF peptides or the body's own MGF. A 2026 review cautions that effects seen with those peptides cannot be assumed to apply to the PEGylated form, since PEGylation alters pharmacokinetics and tissue exposure (Dominikowski et al., 2026).

• Satellite cell activation (proposed) — Muscle satellite cells stay quiescent until activated, when they multiply and fuse with muscle fibers, adding nuclei for growth and repair (Hill & Goldspink, 2003). In rat muscle, MGF expression rose quickly after damage, and its timing suggested that this early pulse triggers satellite cell activation (Hill & Goldspink, 2003). In culture, MGF's E peptide increased myoblast proliferation and held back their final differentiation (Yang & Goldspink, 2002).
• Receptor distinction from mature IGF-1 — Most effects of mature IGF-1 run through the IGF-1 receptor (IGF-1R), a tyrosine kinase that activates the PI3K/Akt and MAPK/ERK pathways; in cell studies, a synthetic peptide from the human Ec domain activated ERK1/2 but not Akt (Philippou et al., 2014). Blocking IGF-1R with an antibody did not stop the E peptide's effect on myoblasts, suggesting a different receptor (Yang & Goldspink, 2002), and the MGF-Ct24E peptide raised human muscle-precursor proliferation by a mechanism other than binding IGF-1R (Mills et al., Am J Transplant 2007). No separate receptor has been identified, though, and studies of rodent E peptides found their effects depended on a working IGF-1R (Philippou et al., 2014).
• PEG shield pharmacokinetics — In PEGylated proteins generally, the PEG chain's hydration shell cuts enzymatic breakdown, and the larger size can reduce elimination by the kidneys (Yang & Lai, 2015). PEG-MGF's own half-life has not been reported (Dominikowski et al., 2026).
• Anti-apoptotic signaling (MGF peptides) — In sheep hearts after an induced infarct, cleaved caspase-3, a marker of cell death, was absent with MGF's E-domain peptide (Carpenter et al., 2008); in gerbils, a synthetic C-terminal MGF peptide protected vulnerable neurons after transient brain ischemia (Dluzniewska et al., 2005).
• Cardioprotective signaling — In sheep with induced heart attacks, MGF's E-domain peptide preserved cardiac function and left 35% less compromised heart muscle than in controls (Carpenter et al., 2008).
• Sustained vs pulsatile signaling — unresolved biology — In rat muscle, MGF expression rises quickly after damage and falls within a few days (Hill & Goldspink, 2003). How long PEG-MGF stays in the body has not been reported (Dominikowski et al., 2026), and none of the studies cited here compares it with unmodified MGF.
• Anti-PEG antibody potential — Repeated doses of PEGylated drugs can trigger antibodies against PEG, which speed the drug's clearance (the "accelerated blood clearance" phenomenon); in people, these antibodies have been tied to lower efficacy for two drugs, PEG-asparaginase and pegloticase (Yang & Lai, 2015). Hypersensitivity is among the possible complications of PEG that clinical experience has raised (Knop et al., 2010). For PEG-MGF the concern is theoretical, carried over from these drugs.
• Anabolic signaling integration — Downstream of satellite cell fusion, PEG-MGF engages the broader muscle-anabolic signaling network (mTOR, p70S6K, 4E-BP1) via its IGF-1-family receptor interactions. This is the mechanistic overlap with GH/IGF-1 axis drugs and part of why PEG-MGF is WADA-banned.

What the Research Shows

No published study has given PEG-MGF to people, and its half-life has not been reported (Dominikowski et al., 2026). None of the studies below tested PEG-MGF itself; they are of MGF biology and of unmodified MGF peptides in cells and animals.

• Muscle regeneration, with the MGF E peptide, not PEG-MGF (Mills et al., Am J Transplant 2007; PMID 17845560) — In mice, the synthetic MGF-Ct24E peptide (not PEGylated), given into the muscle or systemically, improved engraftment of transplanted human muscle precursor cells, an effect the authors attribute to raised proliferation and delayed differentiation. No muscle study of PEG-MGF is among this page's references.
• Myoblast migration, with the MGF E peptide, not PEG-MGF (Mills et al., Exp Cell Res 2007; PMID 17156777) — A synthetic 24-amino-acid peptide from MGF’s E domain (MGF-Ct24E, not PEGylated) made human myogenic precursor cells migrate, in vitro and in vivo: it raised u-PA, u-PAR and MMP-7, lowered PAI-1 activity, and appeared to act without the IGF-1 receptor. No PEGylated MGF was tested.
• Cardiac MI model — native MGF (Carpenter et al., Heart Lung Circ 2008; PMID 17581790) — Demonstrates the cardioprotective signal of the Ec peptide after MI. Foundation for PEG-MGF cardiac-applications extrapolation.
• E-peptide vs mature IGF-1 myoblast biology (Yang & Goldspink, FEBS Lett 2002; PMID 12095637) — Mechanistic foundation: the E-peptide of IGF-1Ec has myoblast-proliferation-specific effects distinct from mature IGF-1. This is why MGF is mechanistically differentiated from the rest of the IGF-1 family.
• Bone and tissue healing preclinical data — Emerging animal data suggest MGF-class peptides support fracture repair via osteogenic progenitor activation.
• Mechanical signaling and IGF-I gene splicing context (Goldspink, Physiology 2005; PMID 16024511) — Foundational review of the MGF/IGF-1Ec splice-variant biology that underlies every MGF derivative, including PEG-MGF.
• IGF-1 muscle overexpression context (Shavlakadze et al., GH IGF Res 2005; PMID 15701567) — Transgenic IGF-1 overexpression context relevant to the PEG-MGF target class.
• No human clinical trials — No published Phase 1 or Phase 2 trials of PEG-MGF exist in the peer-reviewed or registry literature as of April 2026. What exists is community use and preclinical work on unmodified MGF.
• Head-to-head comparisons — None of the studies cited here compares native MGF with PEG-MGF in matched injury or training models. Whether sustained low-level systemic PEG-MGF signaling is biologically equivalent to natural pulsatile local MGF remains an open question.

Human Data

There are no published human clinical trials of PEG-MGF as of April 2026:

• No IND application — No Investigational New Drug application by any sponsor.
• No Phase 1 safety data — Human PK, MTD, and AE profile entirely unknown.
• No registered clinical trial — ClinicalTrials.gov search returns no PEG-MGF trials as of database check.
• Community pharmacovigilance — Bodybuilding and recreational-strength community reports of PEG-MGF use exist in online forums but are not collected systematically; no peer-reviewed case series has been published.
• Where the community doses come from — The 200–400 µg, two or three times a week, in the dosing table is what online protocols describe; PEG-MGF's half-life has not been reported, so no pharmacokinetic data stand behind it (Dominikowski et al., 2026).
• Anti-PEG antibody concerns — class precedent — Anti-PEG antibodies have been tied to faster clearance and lost efficacy for two PEGylated drugs, PEG-asparaginase and pegloticase; with PEG-ADA (Adagen) the antibodies were against the enzyme, not PEG, and with PEG-interferon, pre-existing anti-PEG antibodies did not appear to affect efficacy (Yang & Lai, 2015). Relevance to PEG-MGF use has not been characterized.

Summary: PEG-MGF is sold as a research chemical. There is no human evidence base, and the community doses come from online protocols, not from studies (Dominikowski et al., 2026).

Reconstitution & Storage

Seller listings describe lyophilized PEGylated peptide in 2 mg or 5 mg vials.

• Reconstitution — A seller guide describes mixing with bacteriostatic water and not shaking the vial hard. PEG itself degrades easily under mechanical stress (Knop et al., 2010).
• Storage — A seller guide lists refrigeration after mixing and use within 7–10 days.
• Injection site — Online protocols describe SubQ or IM injection (Dominikowski et al., 2026); a seller guide describes injecting near the trained or injured muscle. No study has compared routes for PEG-MGF.

→ Calculator — vial-to-syringe math

Side Effects & Risks

• No human safety data — No peer-reviewed study has given PEG-MGF to people (Dominikowski et al., 2026).
• Anti-PEG antibody development — Antibodies against PEG can form after repeated doses of PEGylated drugs and speed their clearance; in people they have been tied to lower efficacy of PEG-asparaginase and pegloticase, and some people carry them without ever having received a PEGylated drug (Yang & Lai, 2015). For PEG-MGF the risk is theoretical, carried over from these drugs.
• Injection site reactions — Among the adverse effects reported for the GH–IGF-1 axis peptides used off-label; not documented for PEG-MGF itself, which has no human studies (Dominikowski et al., 2026).
• Hypoglycemia risk (theoretical) — A 2026 review rates low blood sugar a theoretical risk of the IGF-1 analogues it covers, PEG-MGF among them; there are no human data (Dominikowski et al., 2026).
• Cancer risk (theoretical) — In cell studies, synthetic E peptides of human IGF-1 stimulated cell division, and the IGF-1Ec (MGF) transcript has been found in cancerous prostate cells (Philippou et al., 2014); on this preclinical basis, a 2026 review lists a theoretical cell-growth concern for PEG-MGF (Dominikowski et al., 2026).
• Hypersensitivity reactions — Hypersensitivity is among the possible complications of PEG that clinical experience has raised (Knop et al., 2010); with pegloticase, patients carrying anti-PEG antibodies had more infusion reactions, though the antibodies' role is unclear (Yang & Lai, 2015).
• Long-term safety unknown — No study has followed anyone using PEG-MGF; forum reports are anecdotal (Dominikowski et al., 2026).
• Purity / PEGylation quality — It is sold through unregulated supply chains, where product composition and dose are uncertain (Dominikowski et al., 2026). A product without the PEG chain is a different molecule.
• WADA BANNED — As a peptide hormone / growth factor / MGF analog, PEG-MGF is explicitly prohibited under WADA class S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics).
• Drug interactions — None studied. Theoretical with other GH/IGF-1 axis drugs (IGF-1 LR3, tesamorelin, CJC-1295, ipamorelin, sermorelin, growth hormone): a 2026 review names chronic IGF-1 elevation as the central long-term concern of these peptides, theoretical for PEG-MGF (Dominikowski et al., 2026).
• Pregnancy / lactation — No data.

Bloodwork & Monitoring

No trial, label or guideline sets monitoring for PEG-MGF, and no study has given it to people (Dominikowski et al., 2026). A 2026 review written for clinicians lists fasting glucose or HbA1c as worth obtaining in users of any GH–IGF-1 axis peptide; for the IGF-1 analogues, PEG-MGF among them, it rates low blood sugar a theoretical risk (Dominikowski et al., 2026).

Practical User Notes

• WADA status is non-negotiable for competing athletes — Olympic, most professional leagues, NCAA, and federated amateur sport test for MGF-class compounds. PEG-MGF is prohibited for tested athletes in and out of competition. This is the single most important note on this page for competitive-sport users.

Commonly Stacked With

Stacking this? Read the receipt →

→ Calculator — vial-to-syringe math

Legal Status

Related Compounds

People researching PEG-MGF often also look at these:

Next Steps

References

1. Goldspink G. Mechanical signals, IGF-I gene splicing, and muscle adaptation. Physiology (Bethesda). 2005;20:232-238. PMID: 16024511. (Foundational review of MGF / IGF-1Ec biology.)
2. Yang SY, Goldspink G. Different roles of the IGF-I Ec peptide (MGF) and mature IGF-I in myoblast proliferation and differentiation. FEBS Lett. 2002;522(1-3):156-160. PMID: 12095637.
3. Hill M, Goldspink G. Expression and splicing of the insulin-like growth factor gene in rodent muscle is associated with muscle satellite (stem) cell activation following local tissue damage. J Physiol. 2003;549(Pt 2):409-418. PMID: 12692175.
4. Mills P, Dominique JC, Lafrenière JF, Bouchentouf M, Tremblay JP. A synthetic mechano growth factor E Peptide enhances myogenic precursor cell transplantation success. Am J Transplant. 2007;7(10):2247-2259. PMID: 17845560.
5. Mills P, Lafrenière JF, Benabdallah BF, El Fahime el M, Tremblay JP. A new pro-migratory activity on human myogenic precursor cells for a synthetic peptide within the E domain of the mechano growth factor. Exp Cell Res. 2007;313(3):527-537. PMID: 17156777.
6. Carpenter V, Matthews K, Devlin G, Stuart S, Jensen J, Conaglen J, Jeanplong F, Goldspink P, Yang SY, Goldspink G, Bass J, McMahon C. Mechano-growth factor reduces loss of cardiac function in acute myocardial infarction. Heart Lung Circ. 2008;17(1):33-39. PMID: 17581790.
7. Dluzniewska J, Sarnowska A, Beresewicz M, Johnson I, Srai SK, Ramesh B, Goldspink G, Górecki DC, Zabłocka B. A strong neuroprotective effect of the autonomous C-terminal peptide of IGF-1 Ec (MGF) in brain ischemia. FASEB J. 2005;19(13):1896-1898. PMID: 16144956.
8. Riddoch-Contreras J, Yang SY, Dick JR, Goldspink G, Orrell RW, Greensmith L. Mechano-growth factor, an IGF-I splice variant, rescues motoneurons and improves muscle function in SOD1(G93A) mice. Exp Neurol. 2009;215(2):281-289. PMID: 19038252.
9. Shavlakadze T, Winn N, Rosenthal N, Grounds MD. Reconciling data from transgenic mice that overexpress IGF-I specifically in skeletal muscle. Growth Horm IGF Res. 2005;15(1):4-18. PMID: 15701567.
10. Philippou A, Maridaki M, Pneumaticos S, Koutsilieris M. The complexity of the IGF1 gene splicing, posttranslational modification and bioactivity. Mol Med. 2014;20:202-214. PMID: 24637928.
11. Veronese FM, Pasut G. PEGylation, successful approach to drug delivery. Drug Discov Today. 2005;10(21):1451-1458. PMID: 16243265. (Foundational PEGylation pharmacology review.)
12. Knop K, Hoogenboom R, Fischer D, Schubert US. Poly(ethylene glycol) in drug delivery: pros and cons as well as potential alternatives. Angew Chem Int Ed Engl. 2010;49(36):6288-6308. PMID: 20648499. (PEG pharmacology including anti-PEG antibody context.)
13. Yang Q, Lai SK. Anti-PEG immunity: emergence, characteristics, and unaddressed questions. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2015;7(5):655-677. PMID: 25707913. (Anti-PEG antibody review relevant to chronic PEG-MGF exposure.)
14. World Anti-Doping Agency. The 2026 Prohibited List. Montreal: WADA; 2026. (Class S2 prohibition — peptide hormones, growth factors, and mimetics including MGF analogs.)
15. Ates MB, Skolnick AA. Mechano Growth Factor and Its Splice Variants in Muscle Repair and Regeneration. Curr Sports Med Rep. 2021. (Modern overview of MGF and derivatives.)
16. FDA. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the FD&C Act (503A categories list), versions updated April 15, April 22 and May 14, 2026. fda.gov/media/94155/download. Read October 3, 2026. (Notice that 12 peptides would leave Category 2 because their nominations were withdrawn; their removal; GHK-Cu, except injectable, back in Category 1.)
17. Dominikowski A, Rękoś Z, Olejarz M, Szczepanek-Parulska E, Domin R, Ruchała M. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. Front Endocrinol (Lausanne). 2026;17:1822475. doi:10.3389/fendo.2026.1822475. PMID: 42395176. (Online PEG-MGF dosing protocols; no peer-reviewed human study; half-life not reported.)

Related Research

• IGF-1 DESIGF-1 Receptor Agonist (N-terminally Truncated Analog)
• IGF-1 LR3IGF-1 Receptor Agonist (Long R3 Analog)
• MGFIGF-1 Splice Variant / Satellite Cell Activator
• Follistatin-344Myostatin / Activin-Binding Glycoprotein
• FDA TrackerPEG-MGF is one of 12 peptides under FDA Pharmacy Compounding Advisory Committee review for the 503A Bulks List.